Hormone-sensitive, HER-2 Negative Metastatic Breast Cancer
1 clinical trials · Condition
◉ Watch Hormone-sensitive, HER-2 Negative Metastatic Breast Cancer
| Record | Firm | Date |
|---|---|---|
| Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer (NCT01446159) | MedImmune LLC | 2011-06-13 |
Track Hormone-sensitive, HER-2 Negative Metastatic Breast Cancer automatically
Every clearance here is in the API, with alerts when new ones post.